Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Exicure, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $3.33
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS